Skip to main content
. 2017 Jul 21;96(29):e7605. doi: 10.1097/MD.0000000000007605

Figure 2.

Figure 2

Progression-free survival (A) and overall survival (B) of ovarian cancer patients in the non-metformin group and the nondiabetic group.